Funding round brings in $18M for inflammatory drug developer

04/8/2013 | MedCityNews.com

Aquinox Pharmaceuticals, which develops small-molecule therapies for inflammatory disorders, raised $18 million in a Series C funding round from investors including Pfizer and Johnson & Johnson's venture units. The firm says midstage trials of AQX-1125, its lead drug candidate, could begin within months in patients with chronic obstructive pulmonary disease and interstitial cystitis.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI